Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

MOVE

Movano Inc

Feb 13 • 04:00PM ET

11.77

-0.71 -5.69 %

Healthcare • Medical Devices • USA • NASD

Peers: DXCM TNDM NVCR PODD ZBH MASI HOLX INMD LIVN IART

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-22.89	Insider Own	30.35%	Shs Outstand	0.83M	Perf Week	-15.69%
Market Cap	10.71M	Forward P/E	-	EPS next Y	-	Insider Trans	-21.40%	Shs Float	0.63M	Perf Month	70.09%
Enterprise Value	11.92M	PEG	-	EPS next Q	-	Inst Own	5.97%	Short Float	16.69%	Perf Quarter	-1.92%
Income	-17.05M	P/S	21.42	EPS this Y	-	Inst Trans	-5.45%	Short Ratio	0.10	Perf Half Y	96.86%
Sales	0.50M	P/B	-	EPS next Y	-	ROA	-165.32%	Short Interest	0.11M	Perf YTD	41.64%
Book/sh	-2.04	P/C	5.36	EPS next 5Y	-	ROE	-398.78%	52W High	54.40 -78.36%	Perf Year	-77.10%
Cash/sh	2.20	P/FCF	-	EPS past 3/5Y	29.21% 10.24%	ROIC	-	52W Low	4.67 152.03%	Perf 3Y	-94.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-270.20%	Volatility	6.01% 19.29%	Perf 5Y	-
Dividend TTM	-	EV/Sales	23.84	EPS Y/Y TTM	55.97%	Oper. Margin	-3156.20%	ATR (14)	2.41	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.34	Sales Y/Y TTM	-44.57%	Profit Margin	-3409.60%	RSI (14)	47.13	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.70	EPS Q/Q	55.19%	SMA20	-14.00%	Beta	0.87	Target Price	300.00
Payout	-	Debt/Eq	-	Sales Q/Q	60.00%	SMA50	14.19%	Rel Volume	0.04	Prev Close	12.48
Employees	32	LT Debt/Eq	-	Earnings	-	SMA200	44.77%	Avg Volume	1.03M	Price	11.77
IPO	Mar 23, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	30.93% -92.60%	Trades		Volume	44,504	Change	-5.69%

Jan-23-26 09:14AM	Why Is Movano Stock Gaining Today? (Benzinga) +140.17%
01:10AM	Nvidia GPU Deal Sends This Stock Soaring Over 114% After-Hours: Here's What Happened (Benzinga)
Jan-22-26 04:05PM	Corvex Secures Long-Term NVIDIA H200 GPU Deployment with AI-driven Provider of High-Performance Battery Technologies to Support Production AI Workloads (PR Newswire)
Dec-02-25 06:16PM	Checkmate in the Cloud: ServiceNow's Shopping Spree (MarketBeat) +5.98%
Nov-28-25 12:37PM	Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
01:34AM	Loading…
Nov-25-25 01:34AM	Halper Sadeh LLC Encourages JAMF, FRGE, SEE, MOVE Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-11-25 10:30AM	This Penny Stock Just Tripled on an AI Deal. Should You Buy Its Shares Here? (Barchart) +11.67%
Nov-10-25 07:30AM	CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE (PR Newswire) +149.69%
Oct-28-25 04:16PM	Qualcomm Just Hit A 52 Week High-Time to Buckle Up (MarketBeat)
Oct-08-25 08:30AM	Movano Health Announces Reverse Stock Split (PR Newswire)
Aug-29-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +73.25%
Aug-28-25 04:30PM	Movano Health Granted Listing Extension by Nasdaq (PR Newswire)
Aug-22-25 04:15PM	Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q (PR Newswire) +23.01% -10.20%
Jul-11-25 05:30PM	Movano Health Plans to Timely Request a Hearing Before a Nasdaq Hearings Panel (PR Newswire) -9.09% -21.41%
May-23-25 04:05PM	Movano Health Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q (PR Newswire) -9.68%
04:30PM	Loading…
May-16-25 04:30PM	Movano Health's Board of Directors Initiates Process to Maximize Shareholder Value (PR Newswire) -11.96%
Apr-22-25 08:00AM	Movano Health's Proprietary Cuffless Blood Pressure Device Once Again Achieves Accuracy Commensurate with the FDA's Requirements (PR Newswire) -5.86%
Mar-10-25 08:00AM	Movano's Evie Ring Adds New Personalization and Trend Tracking to Support Women's Wellness Journey (PR Newswire) -15.68%
Feb-04-25 08:00AM	Movano Health Commences Clinical Study with New Cuffless Blood Pressure Device (PR Newswire)
Jan-08-25 08:00AM	Movano Health Launches EvieAI Virtual Wellness Assistant (PR Newswire)
Jan-02-25 08:00AM	Movano Health Welcomes Dr. Shaheen Wirk to its Board of Directors (PR Newswire)
Dec-02-24 09:22AM	Movano Health Receives FDA Clearance for EvieMED Ring (PR Newswire) -12.23%
Nov-14-24 04:05PM	Movano Health Reports Q3 2024 Financial Results and Provides Business Update (PR Newswire) -9.04% -8.81%
Nov-07-24 08:00AM	Movano Health Announces Completion of Clinical Study with Cuffless RF Blood Pressure Device (PR Newswire) +5.92%
Nov-06-24 08:00AM	Movano Health to Report Third Quarter 2024 Financial Results on Thursday November 14, 2024 (PR Newswire) +10.76%
Nov-04-24 08:00AM	Movano Health Submits Response to FDA as Part of Final Review Phase for EvieMED (PR Newswire) +5.09%
08:00AM	Movano Health Provides Update on Investigation to Expose Apparent Stock Manipulation Following Reverse Stock Split (PR Newswire)
Oct-31-24 08:30AM	Movano Health Opens Investigation to Expose Apparent Stock Manipulation Following Reverse Stock Split (PR Newswire)
Oct-30-24 09:00AM	Evie Ring Announces Brand Partnership with Lifestyle Content Creator Heidi D'Amelio (PR Newswire) -24.43%
Oct-25-24 09:00AM	Movano Health Announces Reverse Stock Split (PR Newswire) -11.08%
08:00AM	Loading…
Oct-24-24 08:00AM	Movano Health Plans Response Submission to FDA Next Week as Part of EvieMED Final Review Phase (PR Newswire)
Oct-10-24 08:00AM	Movano Health Provides Update on FDA Review of EvieMED Ring (PR Newswire)
Sep-17-24 08:00AM	Evie, Movano Health's Smart Ring for Women, is Back In Stock with Key Upgrades (PR Newswire) +5.11%
Sep-03-24 08:00AM	Movano Health Advances to Final Phase of FDA Review Process for EvieMED Ring (PR Newswire)
Aug-14-24 04:05PM	Movano Health Reports Q2 2024 Financial Results and Provides Business Update (PR Newswire) +6.88%
Aug-05-24 09:00AM	Movano Health to Report Second Quarter 2024 Financial Results on Wednesday August 14, 2024 (PR Newswire) -9.62%
09:00AM	Movano Health Provides Progress Update on EvieMED Regulatory Filing (PR Newswire)
Jun-28-24 09:00AM	Movano Health Announces Dr. Fatima Rodriguez Joining July 11 Virtual Event (PR Newswire)
Jun-13-24 09:00AM	Movano Health Applies Advanced AI through Deep Learning to Deliver Improved Accuracy of Heart Rate in Motion (PR Newswire)
Jun-10-24 09:00AM	MIT Selects Movano Health for Groundbreaking Study on Long COVID and Chronic Lyme Disease (PR Newswire) +7.21%
May-15-24 08:53PM	MOVE Stock Earnings: Movano Reported Results for Q1 2024 (InvestorPlace) +11.93% -6.18%
04:05PM	Movano Health Reports Q1 2024 Financial Results and Provides Business Update (PR Newswire)
May-09-24 08:00AM	Movano Health Submits Exemplary Sp02 Clinical Trial Results in Key Step Towards FDA 510(k) Clearance Decision (PR Newswire)
May-06-24 05:00PM	Movano Health to Report First Quarter 2024 Financial Results on Wednesday May 15, 2024 (PR Newswire)
Apr-05-24 08:00AM	Movano Health Closes $24 Million Private Placement (PR Newswire) +8.07%
Apr-04-24 08:52PM	MOVE Stock Earnings: Movano Reported Results for Q4 2023 (InvestorPlace)
04:30PM	Movano Health Reports 2023 Financial Results and Provides Business Update (PR Newswire)
Apr-03-24 07:00AM	BestGrowthStocks.Com Issues Comprehensive Evaluation of Movano Inc. (News Direct) +8.56%
Apr-02-24 05:01PM	Movano Health Announces $24 Million Private Placement (PR Newswire) +8.86%
05:00PM	Movano Health Secures Strategic Investment from Tier-One Multi-Billion Dollar Medical Device Company (PR Newswire)
04:05PM	Movano Health to Report Fourth Quarter 2023 Financial Results on Thursday, April 4, 2024 (PR Newswire)
Mar-14-24 06:31PM	Evie Ring's Pulse Oximeter Exceeds FDA Accuracy Guidelines in Movano Health's Second Hypoxia Trial (PR Newswire) -12.53%
Jan-22-24 08:00AM	Movano Health Announces Evie Rings Now Shipping (PR Newswire)
Jan-09-24 08:00AM	Movano Health and ams OSRAM Collaborate to Deliver Accurate Lifestyle Monitoring Solutions for Women (PR Newswire) -7.20%
Jan-08-24 07:00AM	Evie, the First Women-Focused Health Ring, Takes 'Smart' to a New Level (PR Newswire)
Dec-18-23 08:00AM	Movano Health Announces HSA/FSA Eligibility for its Women First Wearable, The Evie Ring (PR Newswire)
Dec-12-23 12:00PM	Movano Health Announces Blood Pressure Partnership Forum Following Significant Response to Groundbreaking Accuracy Achievement (PR Newswire)
Dec-05-23 08:00AM	Movano Health's Women-First Wearable, the Evie Ring, Receives 2024 CES Innovation Award (PR Newswire)
Nov-29-23 08:00AM	Movano Health Announces Over $1M Black Friday Holiday Launch Results for the Evie Ring as well as Cuffless Blood Pressure Milestone Achievement (PR Newswire)
Nov-20-23 08:00AM	Evie, the Smart Ring for Women from Movano Health, Available for Order Today (PR Newswire)
Nov-17-23 10:09AM	Movano Health Announces Closing of $4.1 Million Public Offering Including Full Exercise of Over-Allotment Option (PR Newswire)
Nov-16-23 09:45AM	Movano Inc. (NASDAQ:MOVE) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.97%
Nov-15-23 06:02AM	Movano Health Provides Business Update and Reports Third Quarter 2023 Financial Results (PR Newswire) -12.10%
06:00AM	Movano Health Prices $3.6 Million Public Offering (PR Newswire)
Nov-14-23 04:15PM	Movano Inc. to Report Third Quarter 2023 Financial Results on Wednesday, November 15, 2023 (PR Newswire)
04:06PM	Movano Health Announces Proposed Public Offering (PR Newswire)
Nov-03-23 04:05PM	Movano Inc. to Report Third Quarter 2023 Financial Results Tuesday, November 14, 2023 (PR Newswire) -6.11% -6.55%
Oct-31-23 08:00AM	Movano Health's Proprietary Chip and Prototype Achieves Accuracy Commensurate with the FDA's Requirements for Blood Pressure Monitoring (PR Newswire) +9.57%
Oct-30-23 08:00AM	Movano Health to Launch the Evie Ring on November 20 (PR Newswire) +20.51%
Sep-12-23 09:00AM	Evie Ring Welcomes Cardiologist and Stanford University Associate Professor Dr. Fátima Rodriguez to its Medical Advisory Board (PR Newswire)
Aug-30-23 09:00AM	Movano Health, Maker of the Evie Ring, Selects Jay Group as its Fulfillment Provider in Preparation for its Commercial Launch (PR Newswire)
Aug-14-23 04:05PM	Movano Health Provides Business Update and Reports Second Quarter 2023 Financial Results (PR Newswire) -9.02%
Aug-10-23 09:00AM	Evie Ring Establishes Medical Advisory Board Furthering its Commitment to Bringing a Medical-Grade Wearable to Women (PR Newswire)
Aug-08-23 04:30PM	Movano Inc. to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 (PR Newswire)
Aug-03-23 09:00AM	Movano Health Achieves Major Milestone with First FDA Filing for Evie Ring's Pulse Oximeter (PR Newswire)
Jun-21-23 10:49AM	Stock market's fear gauge prices out U.S. recession risk: JPMorgan analyst (Yahoo Finance Video) -11.53%
Jun-15-23 04:05PM	Movano Health Announces Closing of $9.2 Million Public Offering Including Full Exercise of Over-Allotment Option (PR Newswire)
Jun-13-23 08:00AM	Movano Health Prices $8.0 Million Public Offering (PR Newswire) -13.04%
Jun-12-23 04:05PM	Movano Health Announces Proposed Public Offering (PR Newswire)
May-15-23 08:30AM	Movano Health Provides Business Update and Reports First Quarter 2023 Financial Results (PR Newswire) -8.13%
Apr-24-23 09:00AM	Movano Inc. to Report First Quarter 2023 Financial Results on Monday, May 15, 2023 (PR Newswire)
Mar-20-23 08:30AM	Movano Health Provides Business Update and Reports Fourth Quarter 2022 Financial Results (PR Newswire)
Mar-14-23 09:00AM	Movano Health Awarded Three New Core Patents Validating its Cutting-Edge Approach to Radio Frequency-Enabled Glucose and Blood Pressure Monitoring (PR Newswire)
Mar-07-23 09:00AM	What Women Want: Accuracy is Critical to Future Wearable Use (PR Newswire)
Feb-23-23 09:00AM	Movano Inc. to Report Fourth Quarter 2022 Financial Results on Monday, March 20, 2023 (PR Newswire)
Feb-17-23 06:27AM	Daily Vickers Top Buyers & Sellers for 02/17/2023 (Argus Research) -5.00%
Feb-06-23 09:00AM	Movano Health Completes $7.5 Million Public Offering (PR Newswire)
Jan-27-23 08:00AM	Movano Health Prices $6.5 Million Public Offering (PR Newswire) -6.37%
Jan-26-23 04:03PM	Movano Health Announces Proposed Public Offering (PR Newswire) -10.29%
Jan-17-23 09:00AM	Movano Health's Evie Ring Wins 10 "Best of CES 2023" Awards (PR Newswire) -9.76%
Dec-28-22 09:20AM	Movano Health seeks FDA approval for smart ring for women (American City Business Journals)
07:00AM	Movano Health Unveils Evie: First Medical Grade Smart Ring Designed Uniquely for Women (PR Newswire)
Dec-14-22 09:00AM	Movano Health On Track to File First FDA Submission for its Smart Ring's SpO2 and Heart Rate Data Following Successful Pivotal Hypoxia Trial (PR Newswire)
Dec-13-22 09:00AM	Movano Health Announces Launch of Smart Ring Beta Program with Novant Health (PR Newswire) +9.33%
Nov-16-22 09:00AM	Movano Health to Participate in Bernstein CGM Disruptors Conference, BTIG Digital Health Forum and Benchmark Discovery Conference (PR Newswire)
Nov-14-22 04:30PM	Movano Health Provides Business Update and Reports Third Quarter 2022 Financial Results (PR Newswire)
Nov-01-22 04:30PM	Movano Inc. to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 (PR Newswire) -7.55%
Aug-15-22 04:30PM	Movano Inc. Provides Business Update and Reports Second Quarter 2022 Financial Results (PR Newswire)
04:30PM	Movano Announces Beta Program with Stanford University to Advance the Development of Comprehensive Health Data Monitoring for its Wearable Ring Solution (PR Newswire)
Aug-11-22 09:00AM	Movano Expands Go-To-Market Team with Vice President of UX and UI and Vice President of Digital Marketing and Growth (PR Newswire)

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mastrototaro John	Chief Executive Officer	Jan 26 '26	Option Exercise	1.25	72,834	91,042	89,183	Jan 28 05:16 PM
Mastrototaro John	Chief Executive Officer	Jan 27 '26	Sale	20.80	33,069	687,949	56,114	Jan 28 05:16 PM
Cogan Jeremy	CFO	Jan 26 '26	Option Exercise	1.25	64,834	81,042	89,240	Jan 28 05:15 PM
Cogan Jeremy	CFO	Jan 27 '26	Sale	20.78	28,736	597,258	60,504	Jan 28 05:15 PM
John Mastrototaro	Affiliate	Jan 27 '26	Proposed Sale	20.83	32,614	679,426		Jan 27 04:31 PM
Jeremy Cogan	Affiliate	Jan 27 '26	Proposed Sale	20.78	28,736	597,193		Jan 27 04:23 PM
Leabman Michael Aaron	Chief Technology Officer	Jan 14 '26	Sale	6.66	6,845	45,588	22,639	Jan 14 05:30 PM
Leabman Michael Aaron	Chief Technology Officer	Jan 12 '26	Sale	7.01	3,377	23,673	31,560	Jan 14 05:30 PM
Leabman Michael Aaron	Chief Technology Officer	Jan 13 '26	Sale	6.94	2,076	14,407	29,484	Jan 14 05:30 PM
Leabman Michael Aaron	Chief Technology Officer	Jan 06 '26	Option Exercise	1.25	42,250	52,812	42,606	Jan 12 05:53 PM
Leabman Michael Aaron	Chief Technology Officer	Jan 08 '26	Sale	7.26	3,593	26,085	35,720	Jan 12 05:53 PM
Leabman Michael Aaron	Chief Technology Officer	Jan 07 '26	Sale	7.34	3,293	24,171	39,313	Jan 12 05:53 PM
Leabman Michael Aaron	Chief Technology Officer	Jan 09 '26	Sale	7.27	783	5,692	34,937	Jan 12 05:53 PM
Cogan Jeremy	CFO	Jan 05 '26	Option Exercise	1.25	20,000	25,000	25,204	Jan 12 05:53 PM
Cogan Jeremy	CFO	Jan 06 '26	Sale	7.79	8,218	63,985	15,107	Jan 12 05:53 PM
Cogan Jeremy	CFO	Jan 05 '26	Sale	8.35	1,879	15,690	23,325	Jan 12 05:53 PM
Jeremy Cogan	CFO	Jan 07 '26	Proposed Sale	7.84	10,097	79,119		Jan 07 06:15 PM
Mastrototaro John	Chief Executive Officer	Jan 05 '26	Option Exercise	1.25	5,000	6,250	6,944	Jan 07 05:47 PM
Mastrototaro John	Chief Executive Officer	Jan 05 '26	Sale	8.21	2,514	20,640	4,430	Jan 07 05:47 PM
Michael Leabman	Director and CTO	Jan 07 '26	Proposed Sale	7.14	21,000	150,000		Jan 07 11:20 AM

Open in Screener

INAB

IN8bio Inc

Feb 13 • 04:00PM ET

1.78

-0.07 -3.78 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA GILD ADAP CLLS FATE BLUE EDIT IBRX TCRT

| Held by: VXF VTI

Index	-	P/E	-	EPS (ttm)	-6.63	Insider Own	14.53%	Shs Outstand	9.77M	Perf Week	-10.55%
Market Cap	17.39M	Forward P/E	-	EPS next Y	-1.72	Insider Trans	0.00%	Shs Float	8.35M	Perf Month	-19.46%
Enterprise Value	9.66M	PEG	-	EPS next Q	-0.64	Inst Own	31.70%	Short Float	1.60%	Perf Quarter	4.71%
Income	-20.66M	P/S	-	EPS this Y	84.75%	Inst Trans	15.99%	Short Ratio	0.48	Perf Half Y	-25.83%
Sales	0.00M	P/B	0.62	EPS next Y	34.04%	ROA	-126.22%	Short Interest	0.13M	Perf YTD	-23.93%
Book/sh	2.87	P/C	1.63	EPS next 5Y	53.74%	ROE	-189.72%	52W High	10.03 -82.26%	Perf Year	-81.64%
Cash/sh	1.09	P/FCF	-	EPS past 3/5Y	10.02% -13.23%	ROIC	-137.13%	52W Low	1.17 52.14%	Perf 3Y	-96.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.44% 9.80%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	70.57%	Oper. Margin	-	ATR (14)	0.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.91	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	38.79	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.91	EPS Q/Q	81.09%	SMA20	-14.61%	Beta	-0.01	Target Price	6.25
Payout	-	Debt/Eq	0.22	Sales Q/Q	-	SMA50	-11.50%	Rel Volume	0.11	Prev Close	1.85
Employees	18	LT Debt/Eq	0.14	Earnings	Nov 06 AMC	SMA200	-25.97%	Avg Volume	278.41K	Price	1.78
IPO	Jul 30, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	21.62% -	Trades		Volume	29,557	Change	-3.78%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Initiated	Laidlaw	Buy	$7.50
Aug-30-22	Initiated	H.C. Wainwright	Buy	$14

Feb-09-26 08:00AM	IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer (GlobeNewswire)
Feb-03-26 08:00AM	IN8bio to Present at Upcoming Investor and Scientific Conferences in February (GlobeNewswire)
Jan-12-26 08:00AM	IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma (GlobeNewswire) -7.23%
Dec-19-25 08:00AM	IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager (GlobeNewswire) -12.32%
Nov-06-25 04:00PM	IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.63%
08:00AM	Loading…
Oct-29-25 08:00AM	IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site (GlobeNewswire)
Oct-27-25 08:00AM	IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications (GlobeNewswire)
Aug-07-25 04:00PM	IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +7.44%
Jun-09-25 07:00AM	IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial (GlobeNewswire) -26.14%
Jun-02-25 07:30AM	IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival (GlobeNewswire) -9.78%
May-14-25 08:00AM	IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 (GlobeNewswire) -8.31%
May-12-25 08:00AM	IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary ?d T cell Manufacturing Generates Consistent and Robust Clinical Products (GlobeNewswire)
08:00AM	IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary T cell Manufacturing Generates Consistent and Robust Clinical Products (GlobeNewswire)
May-07-25 04:00PM	IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-29-25 08:00AM	IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences (GlobeNewswire)
08:00AM	Loading…
Apr-28-25 08:00AM	IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025 (GlobeNewswire) -5.97%
Mar-31-25 08:00AM	IN8bio to Present New Preclinical Data on Novel Gamma-Delta ( ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 (GlobeNewswire) -15.35%
Mar-18-25 08:05AM	IN8bio to Participate at the 11th Annual Immuno-Oncology 360 Conference 2025 (GlobeNewswire)
Mar-13-25 04:05PM	IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -9.04%
Mar-03-25 09:28AM	IN8bio Announces Advanced Gamma-Delta (?d) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases (GlobeNewswire)
09:28AM	IN8bio Announces Advanced Gamma-Delta ( ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases (GlobeNewswire)
Feb-26-25 08:00AM	IN8bio to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-24-25 08:00AM	IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Feb-14-25 09:00AM	IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML (GlobeNewswire) -10.00%
Feb-11-25 08:00AM	IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients (GlobeNewswire) +13.59%
Jan-06-25 07:00AM	IN8bio to Present at Biotech Showcase 2025 in San Francisco (GlobeNewswire) +19.42%
Dec-10-24 07:00AM	IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting (GlobeNewswire) -9.25%
Dec-02-24 07:00AM	IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference (GlobeNewswire) +20.77%
Nov-25-24 07:00AM	IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-12-24 04:26PM	IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.39% -9.49%
07:00AM	Loading…
07:00AM	IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting (GlobeNewswire)
Nov-05-24 09:00AM	IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +21.10%
Oct-01-24 08:00AM	IN8bio Announces Pricing of $12.4 Million Private Placement (GlobeNewswire)
Sep-05-24 08:33AM	IN8bio cuts staff and pipeline to focus on AML cell therapy (Pharmaceutical Technology) -27.33%
Sep-04-24 04:01PM	IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia (GlobeNewswire) -7.02%
Aug-29-24 06:05AM	IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 08:05AM	IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 (GlobeNewswire) -9.13%
Aug-08-24 04:05PM	IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jun-24-24 08:00AM	IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire)
Jun-14-24 02:04PM	IN8bio Decline After Favorable Leukemia Results Could Be Profit-Taking (Barrons.com) -35.12%
Jun-13-24 04:01PM	IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 (GlobeNewswire) +14.29%
Jun-03-24 06:05AM	IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.40%
May-24-24 08:00AM	IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 (GlobeNewswire)
May-23-24 05:00PM	IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting (GlobeNewswire)
May-14-24 10:00AM	IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress (GlobeNewswire)
May-13-24 08:00AM	IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 (GlobeNewswire)
May-09-24 10:57PM	INAB Stock Earnings: IN8bio Misses EPS for Q1 2024 (InvestorPlace)
04:00PM	IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-30-24 06:05AM	IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire)
Apr-24-24 08:00AM	IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 04:05PM	IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Apr-09-24 04:30PM	IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 (GlobeNewswire)
Mar-14-24 09:54PM	INAB Stock Earnings: IN8bio Misses EPS for Q4 2023 (InvestorPlace) -7.20%
04:00PM	IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 (GlobeNewswire) -7.26%
Feb-26-24 08:00AM	IN8bio to Present at Upcoming Investor Conferences (Business Wire)
Feb-14-24 08:00AM	IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology (GlobeNewswire) -6.67%
Jan-04-24 08:00AM	IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals (GlobeNewswire) +12.10%
Dec-11-23 04:05PM	IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia (GlobeNewswire) +29.29% +27.73%
09:00AM	IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement (GlobeNewswire)
Dec-07-23 08:00AM	IN8bio Appoints Dr. Corinne Epperly to Board of Directors (GlobeNewswire) -5.08%
Dec-05-23 08:00AM	IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia (GlobeNewswire)
Nov-20-23 07:00AM	IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma (GlobeNewswire)
Nov-10-23 07:00AM	IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.61%
Nov-06-23 08:00AM	IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-02-23 09:17AM	IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-23 08:00AM	IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-12-23 08:00AM	IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire) -5.00%
Sep-29-23 08:00AM	IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.31%
Sep-26-23 08:00AM	IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City (GlobeNewswire)
Sep-20-23 08:00AM	IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +12.62%
Sep-19-23 08:03AM	IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents (GlobeNewswire) +7.80%
Sep-06-23 08:00AM	IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-15-23 08:00AM	IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire)
Aug-10-23 04:15PM	IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-23 08:00AM	IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility (GlobeNewswire)
Jun-05-23 08:00AM	IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting (GlobeNewswire) -13.33%
May-17-23 08:00AM	IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer (GlobeNewswire)
May-12-23 08:00AM	IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.80%
May-02-23 05:08PM	IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting (GlobeNewswire) +21.84% +11.32%
May-01-23 08:00AM	IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors (GlobeNewswire) +19.18%
Apr-26-23 10:00AM	IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma (GlobeNewswire) -36.33%
Apr-24-23 08:00AM	IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023 (GlobeNewswire) +185.71%
Apr-17-23 09:00AM	IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023 (GlobeNewswire) +6.61%
Apr-11-23 08:00AM	IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting (GlobeNewswire) +10.66%
Mar-30-23 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.11%
Mar-16-23 08:00AM	IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023 (GlobeNewswire) -7.52%
Mar-01-23 08:00AM	IN8bio to Present at the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) +5.88%
Feb-23-23 07:00AM	IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue (GlobeNewswire) -9.44%
Feb-21-23 07:00AM	IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-17-23 07:00AM	IN8bio to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference (GlobeNewswire)
Jan-05-23 07:00AM	IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals (GlobeNewswire)
Jan-03-23 07:00AM	IN8bio to Present at Biotech Showcase 2023 in San Francisco (GlobeNewswire)
Dec-12-22 07:00AM	IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100 (GlobeNewswire)
Dec-08-22 07:00AM	IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma (GlobeNewswire) -5.26%
Nov-10-22 07:30AM	IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire) +6.38%
Nov-03-22 09:10AM	IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting (GlobeNewswire)

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rochlin Kate	Chief Operating Officer	Apr 30 '25	Option Exercise	0.18	12,295	2,267	55,169	May 07 08:45 PM
McCall Patrick	CHIEF FINANCIAL OFFICER	Apr 30 '25	Option Exercise	0.18	15,000	2,766	67,071	May 07 08:45 PM
Roemer Alan S.	Director	Apr 30 '25	Option Exercise	0.18	113,459	20,922	398,489	May 07 08:45 PM
Brandt Peter C.	Director	Apr 30 '25	Option Exercise	0.18	163,934	30,229	681,538	May 07 08:45 PM

MOVE

Movano Inc

INAB

IN8bio Inc

Upgrade your FINVIZ experience